piperazin-1-yl(tetrahydrofuran-3-yl)methanone | 1070772-28-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: piperazin-1-yl(tetrahydrofuran-3-yl)methanone
• 英文别名: Methanone, 1-piperazinyl(tetrahydro-3-furanyl)-；oxolan-3-yl(piperazin-1-yl)methanone
• CAS: 1070772-28-9
• 化学式: C₉H₁₆N₂O₂
• 分子量: 184.238
• InChiKey: XFWIDOUTQPOITQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-[(3,4-二氢-4-氧代-1-酞嗪基)甲基]-2-氟苯甲酸 、 piperazin-1-yl(tetrahydrofuran-3-yl)methanone 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 生成 4-[[4-fluoro-3-[4-(oxolane-3-carbonyl)piperazine-1-carbonyl]phenyl]methyl]-2H-phthalazin-1-one
  参考文献：
  名称：

  4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1

  摘要：

  Poly(ADP-ribose) polymerase activation is an immediate cellular response to metabolic-, chemical-, or ionizing radiation-induced DNA damage and represents a new target for cancer therapy. In this article, we disclose a novel series of substituted 4-benzyl-2H-phthalazin-1-ones that possess high inhibitory enzyme and cellular potency for both PARP-1 and PARP-2. Optimized compounds from the series also demonstrate good pharmacokinetic profiles, oral bioavailability, and activity in vivo in an SW620 colorectal cancer xenograft model. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one (KU-0059436, AZD2281) 47 is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines. Compound 47 is currently undergoing clinical development for the treatment of BRCA1- and BRCA2-defective cancers.

  DOI：

  10.1021/jm8001263

文献信息

• Regioselectivity of aminomethylation in 3-acetyl-7-hydroxycoumarins: Mannich bases and Betti bases
  作者：Fan Gao、Deng Tao、Cheng Ju、Bei-Bei Yang、Xiu-Qi Bao、Dan Zhang、Tian-Tai Zhang、Li Li

  DOI：10.1039/d1nj01584b

  日期：——

  for anti-inflammatory drug development. In this study, several new 3-acetyl-7-hydroxycoumarin derivatives were designed, synthesized and tested as anti-inflammatory agents. Interestingly, Mannich bases and Betti bases were separately obtained under acidic or neutral conditions. The regioselectivity of aminomethylation was studied based on the atomic electron density distribution by analysing the Voronoi

  7-羟基香豆素是抗发炎药物开发的优先结构。在这项研究中，设计，合成和测试了几种新的3-乙酰基-7-羟基香豆素衍生物作为抗炎药。有趣的是，曼尼希碱和贝蒂碱是在酸性或中性条件下分别获得的。通过分析Voronoi变形密度（VDD）原子电荷，基于原子电子密度分布研究了氨基甲基化的区域选择性，这可以合理地解释实验结果。对一氧化氮（NO）和肿瘤坏死因子α（TNF-α）释放的检测表明，曼尼希碱比相应的贝蒂碱具有更强的抗炎活性。
• 6-Benzyl-6H-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and 6-benzyl-[1,2,4]triazolo[1,5-c]pteridin-5(6H)-one derivatives as PDE1 inhibitors for treating e.g. neurological disorders
  申请人：Dart NeuroScience (Cayman) Ltd

  公开号：EP2861603B1

  公开（公告）日：2018-12-19
• PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS
  申请人：Dart NeuroScience (Cayman) Ltd

  公开号：EP3489238B1

  公开（公告）日：2021-10-13